Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC reduced its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 60.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 40,588 shares of the company's stock after selling 62,079 shares during the quarter. SG Americas Securities LLC owned 0.08% of Viridian Therapeutics worth $884,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of VRDN. JPMorgan Chase & Co. grew its holdings in shares of Viridian Therapeutics by 43.2% during the 1st quarter. JPMorgan Chase & Co. now owns 18,666 shares of the company's stock worth $345,000 after purchasing an additional 5,633 shares in the last quarter. Citigroup Inc. grew its holdings in shares of Viridian Therapeutics by 89.1% during the 1st quarter. Citigroup Inc. now owns 28,140 shares of the company's stock worth $520,000 after purchasing an additional 13,256 shares in the last quarter. Bank of Montreal Can acquired a new stake in shares of Viridian Therapeutics during the 1st quarter worth $414,000. Vanguard Group Inc. grew its holdings in shares of Viridian Therapeutics by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 940,577 shares of the company's stock worth $17,391,000 after purchasing an additional 14,901 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Viridian Therapeutics during the 1st quarter worth $925,000.

Analysts Set New Price Targets

Several analysts recently weighed in on VRDN shares. Royal Bank of Canada restated an "outperform" rating and set a $35.00 price objective on shares of Viridian Therapeutics in a research report on Thursday, December 14th. Oppenheimer upped their price objective on Viridian Therapeutics from $35.00 to $36.00 and gave the stock an "outperform" rating in a research report on Tuesday, December 19th. HC Wainwright restated a "buy" rating and set a $37.00 price objective on shares of Viridian Therapeutics in a research report on Thursday, February 29th. Wedbush upped their price objective on Viridian Therapeutics from $39.00 to $40.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 28th. Finally, Needham & Company LLC restated a "buy" rating and set a $30.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday, March 20th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $36.60.

Insider Buying and Selling

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc bought 476,190 shares of the stock in a transaction on Monday, January 22nd. The stock was acquired at an average cost of $21.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the director now owns 1,839,954 shares in the company, valued at approximately $38,639,034. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.43% of the stock is owned by insiders.

Viridian Therapeutics Trading Down 1.4 %

Viridian Therapeutics stock traded down $0.25 during trading hours on Monday, hitting $17.26. The stock had a trading volume of 608,789 shares, compared to its average volume of 977,277. The company has a quick ratio of 18.26, a current ratio of 18.26 and a debt-to-equity ratio of 0.09. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -3.19 and a beta of 1.07. Viridian Therapeutics, Inc. has a one year low of $10.93 and a one year high of $30.30. The business's 50 day simple moving average is $18.63 and its 200-day simple moving average is $17.53.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its earnings results on Tuesday, February 27th. The company reported ($1.35) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.37). The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.15 million. Viridian Therapeutics had a negative net margin of 75,711.48% and a negative return on equity of 121.80%. Viridian Therapeutics's revenue for the quarter was down 31.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.13) earnings per share. On average, equities analysts predict that Viridian Therapeutics, Inc. will post -4.39 EPS for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.